Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Saved in:
| Title: | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. |
|---|---|
| Authors: | Rahma OE; NRG Oncology, Philadelphia, Pennsylvania.; Department of Medical Oncology, Dana-Farber Cancer Institute/Alliance, Boston, Massachusetts., Yothers G; NRG Oncology, Philadelphia, Pennsylvania.; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Hong TS; NRG Oncology, Philadelphia, Pennsylvania.; Department of Radiation Oncology, Massachusetts General Hospital, Boston., Russell MM; NRG Oncology, Philadelphia, Pennsylvania.; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.; David Geffen School of Medicine at UCLA, Los Angeles, California., You YN; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston., Parker W; NRG Oncology, Philadelphia, Pennsylvania.; Department of Medical Physics, McGill University Health Centre, Montréal, Quebec, Canada., Jacobs SA; NRG Oncology, Philadelphia, Pennsylvania., Colangelo LH; NRG Oncology, Philadelphia, Pennsylvania.; Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Lucas PC; NRG Oncology, Philadelphia, Pennsylvania.; Department of Pathology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Gollub MJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Hall WA; NRG Oncology, Philadelphia, Pennsylvania.; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee., Kachnic LA; NRG Oncology, Philadelphia, Pennsylvania.; Department of Radiation Oncology, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York.; SWOG Cancer Research Network, San Antonio, Texas., Vijayvergia N; NRG Oncology, Philadelphia, Pennsylvania.; Fox Chase Cancer Center, Philadelphia, Pennsylvania., O'Rourke MA; NRG Oncology, Philadelphia, Pennsylvania.; National Cancer Institute Community Oncology Research Program, Prisma Health Cancer Institute, Greenville, South Carolina., Faller BA; Missouri Baptist Medical Center, Heartland Cancer Research, National Cancer Institute Community Oncology Research Program, St Louis., Valicenti RK; Department of Radiation Oncology, UC Davis, Davis, California., Schefter TE; NRG Oncology, Philadelphia, Pennsylvania.; Department of Radiation Oncology, University of Colorado Cancer Center, Aurora., George S; Section of Hematology/Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City., Kainthla R; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas., Stella PJ; NRG Oncology, Philadelphia, Pennsylvania.; Department of Medical Oncology, St Joseph Mercy Hospital, Ann Arbor, Michigan., Sigurdson E; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania., Wolmark N; NRG Oncology, Philadelphia, Pennsylvania.; Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania., George TJ; NRG Oncology, Philadelphia, Pennsylvania.; Department of Medicine, University of Florida Health Cancer Center, Gainesville. |
| Source: | JAMA oncology [JAMA Oncol] 2021 Aug 01; Vol. 7 (8), pp. 1225-1230. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
